NCT07889349
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change.
- Notable Recruitment opened
- Start date changed from estimate of Nov 2026 to Nov 9, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Adverse events (AEs)
Timeframe: From pre-dose to 36 days post-dose.
Secondary (9)
Serum concentration of SHR-3201 after single-dose administration
Area Under the Concentration (AUC) of SHR-3201 after single administration (AUC0-last, AUC0-inf)
Time to peak concentration (Tmax)
Peak concentration (Cmax)
Elimination half-life (T1/2)
Show 4 moreShow less
Clearance (CL)
Steady-state volume of distribution (Vss)
Bioavailability of SHR-3201 following subcutaneous administration
Incidence of anti-drug antibodies (ADA)
Arms and interventions
Dose 1 Group: SHR-3201 + PlaceboExperimental
SHR-3201, SHR-3201 Placebo, in Dose 1.
Dose 2 Group: SHR-3201 + PlaceboExperimental
SHR-3201, SHR-3201 Placebo, in Dose 2.
Dose 3 Group: SHR-3201 + PlaceboExperimental
SHR-3201, SHR-3201 Placebo, in Dose 3.
Dose 4 Group: SHR-3201 + PlaceboExperimental
SHR-3201, SHR-3201 Placebo, in Dose 4.
Dose 5 Group: SHR-3201 + PlaceboExperimental
SHR-3201, SHR-3201 Placebo, in Dose 5.
Drugs: SHR 3201 Injection, SHR 3201 Placebo.
Sites
1 site in 1 country
- The First Affiliated Hospital of University of Science and Technology of ChinaHefei, Anhui, China